MODERN PARADIGM OF COUGHING PATIENT MANAGEMENT
| Autor: | Y. L. MIZERNITSKY, I. M. MELNIKOVA |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Clinical study chemistry.chemical_compound Tracheitis children cough Internal medicine medicine Clinical efficacy media_common rengalin Butamirate citrate Dry cough business.industry release-active drugs General Medicine medicine.disease chemistry Anesthesia Morphine Medicine business Histamine medicine.drug |
| Zdroj: | Медицинский совет, Vol 0, Iss 15, Pp 67-71 (2016) |
| ISSN: | 2658-5790 |
| Popis: | The article presents the results of our studies and literature data in order to evaluate the efficacy and safety of antitussive drug of a new class (Rengalin®) containing release active antibodies to mediators of inflammation to morphine, bradykinin and histamine. Clinical studies in this promising area are not numerous but confirm the results of experimental studies and testify to the efficacy and safety of Rengalin in the cough treatment. The first in Russia clinical study (2012) of the drug Rengalin for the treatment of dry cough in children aged 3 - 10 y.o. (n = 61) with acute respiratory infections (acute rinopharingitis, laryngotracheitis, tracheitis) in a conditions of a clinic showed its clinical efficacy and safety similar to the effect of butamirate citrate (Sinecod®). Data few works of other researchers confirm the data obtained by the authors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|